The FDA has contacted more than 2,200 sponsors and researchers to submit missing clinical trial results to ClinicalTrials.gov, warning that unreported negative data may distort safety and efficacy perceptions.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
The U.S. Food and Drug Administration (FDA) has contacted more than 2,200 medical product companies and researchers to remind them of their legal obligation to submit certain clinical trial results to ClinicalTrials.gov, citing concerns about missing data and publication bias. The agency warned that failure to report negative or inconclusive findings creates gaps in the public record and may distort perceptions of safety and efficacy.
Nearly One-Third of Applicable Studies Lack Results
According to an internal FDA analysis, 29.6% of studies that are highly likely to fall under mandatory reporting requirements do not have results information submitted to ClinicalTrials.gov. These include interventional trials involving FDA-regulated products with a U.S. nexus that are past the reporting deadline. Phase 1 trials and device feasibility studies are excluded from the requirements.
Reporting Requirements and Transparency Concerns
The agency noted that incomplete reporting can overrepresent successful outcomes while underreporting failures, potentially influencing clinical decision-making and research priorities. Sponsors of applicable clinical trials are generally required to submit results within one year after trial completion.
FDA Outreach Targets More Than 3,000 Trials
On March 30, 2026, the FDA sent messages to responsible parties associated with more than 3,000 registered clinical trials, including some publicly funded studies. The notices were directed to sponsors who appear not to have submitted required results information or who may not have completed the quality control review conducted by the National Library of Medicine. The agency described the outreach as an effort to encourage voluntary compliance before considering further regulatory action.
Commissioner Highlights Ethical Obligation to Disclose Data
FDA Commissioner Marty Makary said withholding unfavorable findings undermines transparency and patient care, emphasizing that sponsors have an ethical obligation to disclose results regardless of financial impact. He added that clinicians rely on complete evidence when deciding whether to prescribe medications, and missing data limits informed decision-making.
Agency Signals Possible Compliance Actions
The FDA also indicated it may issue Pre-Notices of Noncompliance and formal Notices of Noncompliance as part of risk-based enforcement. The March 30 outreach represents an additional step to allow sponsors to comply with federal law before escalation.
CDER Leadership Backs Transparency Initiative
Tracy Beth Hoeg, Acting Director of the Center for Drug Evaluation and Research, said the initiative aims to improve timely reporting of interventional studies and strengthen transparency around investigational and approved products. She noted that broader disclosure of results could improve patient safety and help researchers better understand the benefits and risks of medical products.
Reference
FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results | FDA, 13 April 2026
About the Writer
Samiksha Vikram Jadhav is a B.Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She has a keen interest in healthcare advancements, clinical research, medical writing, and emerging therapies. Her work focuses on presenting developments in the pharmaceutical and healthcare sectors through clear and accurate scientific communication.